Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Prostate cancer proteomics: The urgent need for clinically validated biomarkers

Evans, Caroline A., Glen, Adam, Eaton, Colby L., Larré, Stéphane, Catto, James W. F., Hamdy, Freddie C., Wright, Phillip C. and Rehman, Ishtiaq 2009. Prostate cancer proteomics: The urgent need for clinically validated biomarkers. Proteomics - Clinical Applications 3 (2) , pp. 197-212. 10.1002/prca.200800154

Full text not available from this repository.

Abstract

Prostate cancer (PCa) is the most common cancer diagnosis and the second most common cause of cancer-related deaths in men. Currently, serum prostate-specific antigen (PSA) is the only biomarker widely used in the diagnosis and management of patients with PCa. However, PSA lacks diagnostic sensitivity and specificity, leading to false-negative and false-positive test results. PSA cannot distinguish indolent from aggressive disease, leading to many patients being over-treated with associated side-effects. Furthermore, PSA is unable to identify which tumors are likely to become unresponsive to treatment at an early stage. Thus, there is an urgent need for clinically validated biomarkers which will improve the diagnosis and management of PCa. Given the heterogeneity of PCa it is likely that a panel of biomarkers will be required. In the quest for PCa biomarkers, a wide range of samples including urine, serum, tissues, and cell lines have been studied using proteomic approaches such as 2-DE, SELDI-TOF, SILAC, ICAT, iTRAQ, and MALDI-IMS. The value of these technologies, and other emerging platforms such as selected reaction monitoring (SRM) and multiple reaction monitoring (MRM), are discussed in the context of biomarker discovery, validation and addressing the “bottle-necks” that exist prior to clinical translation.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Dentistry
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords: ICAT; iTRAQ; MRM; SELDI-TOF-MS; SILAC; SRM
Publisher: John Wiley and Sons
ISSN: 1862-8346
Last Modified: 10 Oct 2017 14:28
URI: http://orca.cf.ac.uk/id/eprint/32408

Citation Data

Cited 7 times in Google Scholar. View in Google Scholar

Cited 7 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item